Imagine a way to deep-clean medical tools using a special kind of 'energized air' instead of harsh chemicals. It works like a lightning bolt in a controlled box, zapping away bacteria and viruses without using heat that would melt plastic or damage electronics. This means tools are safer for patients and better for the planet.
Medical device manufacturers and hospitals are trapped between ineffective sterilization and toxic chemicals like EtO that cause cancer and pollution. Current alternatives cannot keep up with a 5-7% annual growth in production or handle complex, heat-sensitive materials.
An In Situ Cold Plasma Sterilization system that converts air gases into a sterilizing agent without using chemicals or radiation.
If you are a hospital dealing with high contamination rates where 1 in 5 endoscopes fail safety standards — this project developed a cold plasma process that destroys all biothreats without using toxic chemicals. This ensures patient safety and reduces the need to quarantine devices.
If you are a manufacturer dealing with regulatory pressure to stop using Ethylene Oxide (EtO) due to cancer risks — this project developed a chemical-free sterilization technology. It allows you to maintain a 5-7% annual production growth without the environmental and health liabilities of EtO.
If you are a company designing devices with sensitive polymers and electronics that cannot withstand heat or radiation — this project developed a non-thermal plasma process. It preserves the physical integrity of fragile components while ensuring total sterilization.
Based on available project data, specific pricing and cost structures are not provided.
Yes, the project aims to reach TRL9 to allow the technology to be deployed Europe- and US-wide to replace current industrial solutions.
Based on available project data, specific licensing terms are not mentioned, but the technology is developed by AURORA (SME).
Yes, it is designed to replace Ethylene Oxide (EtO), which faces increasing political and regulatory pressure due to air and water pollution.
The project period runs from 2023-12-01 to 2025-05-31, aiming to move the technology from TRL6 to TRL9.
The project is led by a single French SME, AURORA, which holds 100% of the industry ratio. This lean structure suggests a highly focused commercialization effort, leveraging 12 years of internal R&D to move a proprietary technology directly from a validated prototype to market readiness.
Contact AURORA in France
Contact us to facilitate a partnership with AURORA for plasma sterilization integration.
